Alzamend Neuro gets positive FDA feedback on development of lead drug

Alzamend Neuro

18/07/2022 13:44

** Shares of Alzamend Neuro  ALZN.O  rise as much as 7.5% to
$1 before trading flat premarket
    ** ALZN says it received feedback from the U.S. FDA which
provides a path forward for the planned development of its lead
drug candidate, AL001, for the treatment of bipolar disorder,
major depressive disorder and post-traumatic stress disorder
(PTSD)  urn:newsml:reuters.com:*:nBwbXxLMta
    ** The drug is currently in a mid-stage trial, being tested
as a potential treatment of dementia related to Alzheimer's
disease
    ** Based on the FDA's feedback, co expects to file
applications to start clinical studies of the drug in the newer
indications upon completion of the mid-stage trial
    ** Stock had more than halved in value YTD up to the last
close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))